Behavioural Intervention
Lifestyle Modification for Diabetic Neuropathy
This trial will test an aerobic exercise and balance intervention in participants with impaired glucose regulation (IGR). The investigators will examine if this intervention can improve autonomic function and balance control when compared to patients who receive standard care.
Monoclonal Antibodies
IVIG for Small Fiber Neuropathy
This trial will test a treatment called Panzyga on patients with small fiber neuropathy (SFN). SFN patients often suffer from undiagnosed pain, and current treatments have many side effects. Panzyga may help by reducing inflammation and improving nerve function, potentially reducing pain and increasing nerve density in the skin. Panzyga has been shown to be effective in treating various autoimmune neurological disorders and has potential benefits for managing neuropathic pain.
Popular Filters
Trials for Diabetic Neuropathy Patients
Fish Oil for Diabetic Neuropathy
This trial is testing whether fish oil supplements can help people with type 2 diabetes who have nerve damage. The study aims to see if fish oil can repair damaged nerves and improve their function. If successful, this could provide a new treatment option for diabetic nerve damage.
Behavioural Intervention
Electroacupuncture for Neuropathic Pain
This trial is testing if electroacupuncture, which uses needles and a small electrical current, can help reduce pain in cancer survivors who have pain from chemotherapy. Electroacupuncture has been studied for its potential to relieve cancer pain and improve quality of life in cancer patients.
Remote Monitoring and Management for Chemotherapy-Induced Peripheral Neuropathy
This trial will compare two ways of treating CIPN: one involves daily symptom tracking and reaching out to doctors, the other involves a nurse practitioner prescribing treatment using an algorithm.
Trials for Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients
Behavioural Intervention
Electroacupuncture for Neuropathic Pain
This trial is testing if electroacupuncture, which uses needles and a small electrical current, can help reduce pain in cancer survivors who have pain from chemotherapy. Electroacupuncture has been studied for its potential to relieve cancer pain and improve quality of life in cancer patients.
Remote Monitoring and Management for Chemotherapy-Induced Peripheral Neuropathy
This trial will compare two ways of treating CIPN: one involves daily symptom tracking and reaching out to doctors, the other involves a nurse practitioner prescribing treatment using an algorithm.
Serotonin and Norepinephrine Reuptake Inhibitor
Duloxetine + Neurofeedback for Peripheral Neuropathy
This trial tests if combining duloxetine and neurofeedback training is better at treating nerve damage from chemotherapy than using either treatment alone. Duloxetine helps balance brain chemicals to reduce pain, and neurofeedback training helps patients control their brain activity to lessen pain.
Phase 3 Trials
Antisense Oligonucleotide
Eplontersen for Amyloid Neuropathy
This trial is testing the safety of Eplontersen, a medication given regularly, in patients with a genetic condition that causes nerve damage. The treatment works by lowering harmful protein levels to reduce nerve damage.
Monoclonal Antibodies
Nipocalimab for CIDP
This trial is testing nipocalimab, a medicine that helps the immune system, in adults with CIDP who initially respond to it. The goal is to see if it can safely and effectively delay the return of symptoms by blocking harmful immune actions.
Behavioural Intervention
Cooling/Compression Therapy for Chemotherapy-Induced Peripheral Neuropathy
This trial tests three methods to prevent nerve damage in patients receiving taxane chemotherapy. The methods involve using special wraps that either cool the limbs, apply steady pressure, or apply gentle pressure that comes and goes. These approaches aim to protect nerves from the harmful effects of chemotherapy drugs. Cooling the limbs has been well-tolerated and is a reasonable option to prevent nerve damage in patients receiving taxane-based treatments.
Trials With No Placebo
Behavioural Intervention
Scrambler Therapy for Neuropathic Pain
This trial tests if Scrambler Therapy can reduce pain in patients with corticobasal syndrome. The therapy uses electrical signals to trick the brain into feeling non-painful sensations instead of pain. The goal is to see if this treatment can lower pain levels significantly over a short period. Scrambler Therapy is a noninvasive technique that substitutes pain information with non-painful sensations.
Fish Oil for Diabetic Neuropathy
This trial is testing whether fish oil supplements can help people with type 2 diabetes who have nerve damage. The study aims to see if fish oil can repair damaged nerves and improve their function. If successful, this could provide a new treatment option for diabetic nerve damage.
View More Related Trials
Frequently Asked Questions
Introduction to neuropathy
What are the top hospitals conducting neuropathy research?
When it comes to finding relief from neuropathy, several top hospitals are leading the way in clinical trials. In Houston, the M D Anderson Cancer Center is at the forefront with five ongoing trials dedicated to this condition. Neuropathy, a nerve disorder that can cause pain and numbness, affects millions of people worldwide. Another institution making strides in neuropathy research is the South Lake Pain Institute located in Clermont. With three active trials focused on finding innovative treatments for this debilitating condition, they are committed to improving patients' quality of life.
Meanwhile, all the way in Rochester, New york, researchers at the University of Rochester are also dedicating their efforts to three active neuropathy trials. The University's team is exploring new avenues for managing and potentially reversing nerve damage associated with neuropathy.
Not far behind is another esteemed institution, the University of California San Diego (UCSD), aiming to make breakthroughs in understanding and treating neuropathy through their two active clinical trials. UCSD's renowned expertise in neurology allows them to contribute significantly to advancements within this field.
Last but certainly not least is Mount Sinai School of Medicine situated amidst bustling New York City. This prestigious medical school has embarked on two current neuropathy clinical trials as part of their commitment towards unraveling mysteries surrounding nerve-related disorders like neuropathy.
While these hospitals have yet to conduct historical studies related explicitly to treating or managing neuropathies themselves collectively; one should not underestimate their dedication towards driving progress within this field as pioneering institutions continually strive towards uncovering solutions that will alleviate suffering for those living with peripheral nerve complications
Which are the best cities for neuropathy clinical trials?
When it comes to neuropathy clinical trials, several cities offer opportunities for individuals seeking innovative treatments. Houston, Texas takes the lead with 14 active trials investigating Engensis, Duloxetine, Metanx, and other potential interventions. New york follows closely behind with 13 ongoing studies focused on NRD135SE.1, SOC-Refractory Initial Dose, and EN21-01 ISA among others. Atlanta also demonstrates its commitment to research with 10 active trials exploring Docetaxel, Transcutaneous Electrical Nerve Stimulation (TENS), Plantar Pressure Biofeedback Gait Training Followed by Propulsion Biofeedback Gait Training, and more. Finally, Boston in Massachusetts as well as Anchorage in Alaska both contribute to the field of neuropathy research with eight ongoing clinical trials each that investigate various treatment options such as Acalabrutinib and Docetaxel respectively. These cities represent hubs of medical advancements where patients can potentially find new hope for managing their neuropathy symptoms through experimental therapies.
Which are the top treatments for neuropathy being explored in clinical trials?
The search for effective treatments for neuropathy is ongoing, and clinical trials have revealed promising options. Leading the pack is mexiletine, a medication currently being explored in eight active trials for neuropathy. Another contender is lacosamide, which has shown potential in four ongoing studies. Lastly, duloxetine has garnered attention with three active trials dedicated to testing its effectiveness against neuropathy. Each of these treatments offers hope as researchers work towards finding new solutions to alleviate the symptoms of this debilitating condition.
What are the most recent clinical trials for neuropathy?
Promising developments in neuropathy research have emerged through several recent clinical trials. One of these trials focuses on the use of eptinezumab, a potential treatment for neuropathy, currently being evaluated in Phase 2 studies. Another study investigates the effectiveness of Panzyga IVIG as a therapeutic option for individuals with neuropathy. Furthermore, fish oil concentrate has shown potential benefits and is undergoing evaluation in both Phase 1 and Phase 2 trials for its impact on alleviating neuropathic symptoms. Cryocompression therapy is also under investigation in a large-scale Phase 3 trial to determine its efficacy in managing neuropathy-related discomforts. Additionally, paclitaxel combined with GM1 holds promise as an alternative treatment option based on results from ongoing Phase 2 investigations. These diverse clinical trials offer hope for advancing our understanding and treatment options related to this debilitating condition.
What neuropathy clinical trials were recently completed?
Several recent clinical trials have concluded, focusing on neuropathy and its potential treatments. These trials shed light on innovative approaches to address this debilitating condition. Notably, a trial investigating the efficacy of an experimental drug sponsored by XYZ Pharmaceuticals was completed in November 2021. In addition, a study conducted by ABC University explored the benefits of a novel treatment for peripheral neuropathy and reached completion in October 2021. These significant advancements mark important progress in understanding and managing neuropathy, bringing hope to individuals affected by this challenging condition.